Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome

被引:2
|
作者
Ranganathan, Megha [1 ]
Sacca, Rosalba E. [1 ]
Trottier, Magan [1 ]
Maio, Anna [1 ]
Kemel, Yelena [2 ]
Salo-Mullen, Erin [1 ]
Catchings, Amanda [1 ]
Kane, Sarah [1 ]
Wang, Chiyun [3 ]
Ravichandran, Vignesh [2 ]
Ptashkin, Ryan [3 ]
Mehta, Nikita [3 ]
Garcia-Aguilar, Julio [4 ,5 ]
Weiser, Martin R. [4 ,5 ]
Donoghue, Mark T. A. [6 ]
Berger, Michael F. [3 ,6 ,7 ]
Mandelker, Diana [3 ]
Walsh, Michael F. [1 ,2 ,8 ]
Carlo, Maria [1 ,2 ,8 ]
Liu, Ying L. [1 ,2 ,8 ]
Cercek, Andrea [1 ,8 ]
Yaeger, Rona [1 ,8 ]
Saltz, Leonard [1 ,8 ]
Segal, Neil H. [1 ,8 ]
Mendelsohn, Robin B. [1 ,8 ]
Markowitz, Arnold J. [1 ,8 ]
Offit, Kenneth [1 ,2 ,8 ]
Shia, Jinru [3 ]
Stadler, Zsofia K. [1 ,2 ,8 ]
Latham, Alicia [1 ,2 ,8 ,9 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Niehaus Ctr Inherited Canc Genom, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY USA
[5] Weill Cornell Med Coll, Dept Surg, New York, NY USA
[6] Mem Sloan Kettering Canc Ctr, Marie Josee & Henry R Kravis Ctr Mol Oncol, New York, NY 10017 USA
[7] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY USA
[8] Weill Cornell Med Coll, Dept Med, New York, NY USA
[9] Mem Sloan Kettering Canc Ctr, 222 E70th St,Room 406, New York, NY 10021 USA
关键词
MICROSATELLITE-INSTABILITY; INTERVAL CANCERS; COLON; EPCAM; CHEMOTHERAPY; FEASIBILITY; ASSOCIATION; STATISTICS; GUIDELINES; MUTATIONS;
D O I
10.1200/PO.22.00675
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSELynch syndrome (LS)-associated colorectal cancer (CRC) is characterized by mismatch repair-deficiency (MMR-D) and/or microsatellite instability (MSI). However, with increasing utilization of germline testing, MMR-proficient (MMR-P) and/or microsatellite stable (MSS) CRC has also been observed. We sought to characterize MMR-P/MSS CRC among patients with LS. METHODSPatients with solid tumors with germline MMR pathogenic/likely pathogenic (P/LP) variants were identified on a prospective matched tumor-normal next-generation sequencing (NGS) protocol. CRCs were evaluated for MMR-D via immunohistochemical (IHC) staining and/or MSI via NGS. Clinical variables were correlated with MMR status using nonparametric tests. RESULTSAmong 17,617 patients with solid tumors, 1.4% (n = 242) had LS. A total of 36% (86 of 242) of patients with LS had at least one CRC that underwent NGS profiling, amounting to 99 pooled CRCs assessed. A total of 10% (10 of 99) of CRCs were MMR-P, with 100% concordance between MSS status and retained MMR protein staining. A total of 89% (8 of 9) of patients in the MMR-P group had MSH6 or PMS2 variants, compared with 30% (23 of 77) in the MMR-D group (P = .001). A total of 46% (6 of 13) of PMS2+ patients had MMR-P CRC. The median age of onset was 58 and 43 years for MMR-P and MMR-D CRC, respectively (P = .07). Despite the later median age of onset, 40% (4 of 10) of MMR-P CRCs were diagnosed <50. A total of 60% (6 of 10) of MMR-P CRCs were metastatic compared with 13% (12 of 89) of MMR-D CRCs (P = .002). A total of 33% (3 of 9) of patients with MMR-P CRC did not meet LS testing criteria. CONCLUSIONPatients with LS remained at risk for MMR-P CRC, which was more prevalent among patients with MSH6 and PMS2 variants. MMR-P CRC was later onset and more commonly metastatic compared with MMR-D CRC. Confirmation of tumor MMR/MSI status is critical for patient management and familial risk estimation.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond
    Willis, Jason A.
    Overman, Michael J.
    Vilar, Eduardo
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (17) : 5185 - 5187
  • [2] Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients
    Shou-Sheng Liu
    Yuan-Zhong Yang
    Chang Jiang
    Qi Quan
    Qian-Kun Xie
    Xiao-Pai Wang
    Wen-Zhuo He
    Yu-Ming Rong
    Ping Chen
    Qiong Yang
    Lin Yang
    Bei Zhang
    Xiao-Jun Xia
    Peng-Fei Kong
    Liang-Ping Xia
    [J]. Journal of Translational Medicine, 16
  • [3] Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer
    Murphy, Adrian Gerard
    Walker, Rosalind
    Lutz, Eric R.
    Parkinson, Rose
    Ahuja, Nita
    Zheng, Lei
    Jaffee, Elizabeth M.
    Azad, Nilofer Saba
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [4] Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients
    Liu, Shou-Sheng
    Yang, Yuan-Zhong
    Jiang, Chang
    Quan, Qi
    Xie, Qian-Kun
    Wang, Xiao-Pai
    He, Wen-Zhuo
    Rong, Yu-Ming
    Chen, Ping
    Yang, Qiong
    Yang, Lin
    Zhang, Bei
    Xia, Xiao-Jun
    Kong, Peng-Fei
    Xia, Liang-Ping
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [5] Immunoscore in mismatch repair-proficient and -deficient colon cancer
    Wirta, Erkki-Ville
    Seppala, Toni
    Friman, Marjukka
    Vayrynen, Juha
    Ahtiainen, Maarit
    Kautiainen, Hannu
    Kuopio, Teijo
    Kellokumpu, Ilmo
    Mecklin, Jukka-Pekka
    Bohm, Jan
    [J]. JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2017, 3 (03): : 203 - 213
  • [6] Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients
    Lugli, Alessandro
    Vlajnic, Tatjana
    Giger, Olivier
    Karamitopoulou, Eva
    Patsouris, Efstratios S.
    Peros, George
    Terracciano, Luigi M.
    Zlobec, Inti
    [J]. HUMAN PATHOLOGY, 2011, 42 (12) : 1833 - 1840
  • [7] Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer
    Eppenberger, Manuela
    Zlobec, Inti
    Baumhoer, Daniel
    Terracciano, Luigi
    Lugli, Alessandro
    [J]. BMC CANCER, 2010, 10
  • [8] Immune features and neoantigen recognition in mismatch repair-proficient colorectal cancer liver metastases
    Hebert, Steven
    Mathieu, Melissa
    Henault, David
    Marques, Maud
    Audemard, Eric
    Courcelles, Mathieu
    Brown, Scott D.
    Wirapati, Pratyaksha
    Tejpar, Sabine
    D'Angelica, Michael I.
    Holt, Robert A.
    Mader, Sylvie
    Thibault, Pierre
    Batist, Gerald
    Kleinman, Claudia
    Turcotte, Simon
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [9] Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer
    Manuela Eppenberger
    Inti Zlobec
    Daniel Baumhoer
    Luigi Terracciano
    Alessandro Lugli
    [J]. BMC Cancer, 10
  • [10] Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer
    Pilar Garre
    Lorena Martín
    Inmaculada Bando
    Alicia Tosar
    Patricia Llovet
    Julián Sanz
    Atocha Romero
    Miguel de la Hoya
    Eduardo Díaz-Rubio
    Trinidad Caldés
    [J]. Familial Cancer, 2014, 13 : 109 - 119